Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Faran Shimi Pharmaceutical Company","sponsor":"Quantum Genomics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$12.1 million","newsHeadline":"Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Faran","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"IRAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by Faran Shimi Pharmaceutical Company

    Menu

    Faran Shimi Pharmaceutical Company

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Faran Shimi Pharmaceutical Company

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Iran
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Faran

              Details:

              Under the terms of the agreement, Faran will receive the exclusive rights to market Firibastat for the treatment of difficult-to-treat / resistant hypertension in Greece.

              Lead Product(s): Firibastat

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: QGC001

              Highest Development Status: Phase III Product Type: Small molecule

              Recipient: Quantum Genomics

              Deal Size: Undisclosed Upfront Cash: $12.1 million

              Deal Type: Collaboration December 15, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY